All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Prosensa Therapeutics BV and GlaxoSmithKline plc are moving forward with three additional exon-skipping antisense oligonucleotides as part of their alliance in Duchenne's muscular dystrophy (DMD).